Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 8/20 | 0.38 |
| ▸ | CMA1 | P23946 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17733999 | 1.00 | CTRB1 (0.41) | CTRB1TUBB1SLC6A2TACR1CMA1 | |
| SCHEMBL13848659 | 1.00 | CTRB1 (0.41) | CTRB1TUBB1SLC6A2TACR1CMA1 | |
| SCHEMBL13682340 | 1.00 | CTRB1 (0.41) | CTRB1TUBB1SLC6A2TACR1CMA1 | |
| SCHEMBL59463 | 1.00 | CTRB1 (0.41) | CTRB1TUBB1SLC6A2TACR1CMA1 | |
| SCHEMBL17734047 | 1.00 | CTRB1 (0.41) | CTRB1TUBB1SLC6A2TACR1CMA1 | |
| SCHEMBL59201 | 0.91 | TUBB1 (0.44) | TUBB1ELANE | |
| SCHEMBL13682364 | 0.91 | TUBB1 (0.44) | TUBB1ELANE | |
| SCHEMBL17734027 | 0.91 | TUBB1 (0.44) | TUBB1ELANE | |
| SCHEMBL59486 | 0.89 | TACR1 (0.42) | TUBB1TACR1ELANE | |
| SCHEMBL15430034 | 0.89 | CMA1 (0.43) | TACR1CMA1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | CTRB1 520/4885TUBB1 1330/4885SLC6A2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.